LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | XMD16-144 | 1.11 | uM | LJP5 | 3 | M09 | 72 | hr | 2543 | 2184 | 5760 | 0.3791 | -0.1212 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 2543 | 2227 | 5734 | 0.3884 | -0.1071 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 2543 | 2372 | 5761 | 0.4117 | -0.0574 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 2543 | 2188 | 5760 | 0.3798 | -0.1198 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 1 | M07 | 72 | hr | 2543 | 1439 | 5734 | 0.2509 | -0.3847 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 2 | M07 | 72 | hr | 2543 | 1430 | 5761 | 0.2482 | -0.3863 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 3 | M07 | 72 | hr | 2543 | 1349 | 5760 | 0.2342 | -0.4159 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 1 | M24 | 72 | hr | 2543 | 4881 | 5734 | 0.8512 | 0.7433 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 2 | M24 | 72 | hr | 2543 | 4751 | 5761 | 0.8246 | 0.6984 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 3 | M24 | 72 | hr | 2543 | 4844 | 5760 | 0.8409 | 0.7267 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 2543 | 5526 | 5734 | 0.9636 | 0.9378 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 2 | M23 | 72 | hr | 2543 | 5526 | 5761 | 0.9591 | 0.9305 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 3 | M23 | 72 | hr | 2543 | 5556 | 5760 | 0.9644 | 0.9395 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 2543 | 5827 | 5734 | 1.0161 | 1.0275 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 2 | M22 | 72 | hr | 2543 | 5700 | 5761 | 0.9893 | 0.9819 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 3 | M22 | 72 | hr | 2543 | 6056 | 5760 | 1.0512 | 1.0865 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 2543 | 5570 | 5734 | 0.9713 | 0.9510 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 2543 | 5484 | 5761 | 0.9519 | 0.9181 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 2543 | 5796 | 5760 | 1.0061 | 1.0103 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 2543 | 5643 | 5734 | 0.9840 | 0.9728 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 2543 | 5633 | 5761 | 0.9777 | 0.9621 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 2543 | 5547 | 5760 | 0.9629 | 0.9369 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 1 | M19 | 72 | hr | 2543 | 2568 | 5734 | 0.4478 | 0.0082 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 2 | M19 | 72 | hr | 2543 | 2585 | 5761 | 0.4487 | 0.0138 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 3 | M19 | 72 | hr | 2543 | 2840 | 5760 | 0.4930 | 0.0980 |